BR112014033066A2 - método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo. - Google Patents
método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo.Info
- Publication number
- BR112014033066A2 BR112014033066A2 BR112014033066A BR112014033066A BR112014033066A2 BR 112014033066 A2 BR112014033066 A2 BR 112014033066A2 BR 112014033066 A BR112014033066 A BR 112014033066A BR 112014033066 A BR112014033066 A BR 112014033066A BR 112014033066 A2 BR112014033066 A2 BR 112014033066A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- humanized
- alzheimer
- chimeric
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667891P | 2012-07-03 | 2012-07-03 | |
| PCT/US2013/046399 WO2014007982A2 (en) | 2012-07-03 | 2013-06-18 | C-terminal and central epitope a-beta antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014033066A2 true BR112014033066A2 (pt) | 2017-08-01 |
Family
ID=49882576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014033066A BR112014033066A2 (pt) | 2012-07-03 | 2013-06-18 | método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150353631A1 (pt) |
| EP (1) | EP2869846A4 (pt) |
| JP (1) | JP2015526409A (pt) |
| KR (1) | KR20150036163A (pt) |
| CN (1) | CN105579061A (pt) |
| AU (1) | AU2013287119A1 (pt) |
| BR (1) | BR112014033066A2 (pt) |
| CA (1) | CA2877516A1 (pt) |
| HK (1) | HK1208810A1 (pt) |
| IL (1) | IL236549A0 (pt) |
| MX (1) | MX2014015744A (pt) |
| RU (1) | RU2014153675A (pt) |
| WO (1) | WO2014007982A2 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 |
| BR112017001385B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| KR102476226B1 (ko) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| WO2017087965A1 (en) * | 2015-11-20 | 2017-05-26 | Navidea Biopharmaceuticals, Inc. | Formulations for 2-heteroaryl substituted benzofurans |
| CN105542005B (zh) * | 2016-02-03 | 2018-11-09 | 大连理工大学 | 一种抗人淀粉样β肽的纳米抗体及其应用 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| WO2023111168A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2301725C (en) * | 1997-08-28 | 2008-11-18 | University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TR200202799T3 (tr) * | 2000-02-24 | 2003-03-21 | Washington University St.Louis | AB peptidini sekanslayan insanlaştırılmış antikorlar |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| PE20061401A1 (es) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
| RU2007124933A (ru) * | 2005-01-28 | 2009-03-10 | Вайет (Us) | Стабилизированные жидкие полипептидные составы |
| RU2015111675A (ru) * | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
| EP2185592B1 (en) * | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| WO2011133919A1 (en) * | 2010-04-22 | 2011-10-27 | Janssen Alzheimer Immunotherapy | Use of tau to monitor immunotherapy |
| EP2538982A4 (en) * | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | PET SURVEILLANCE OF IMMUNOTHERAPY DIRECTED AGAINST |
-
2013
- 2013-06-18 BR BR112014033066A patent/BR112014033066A2/pt active Search and Examination
- 2013-06-18 CA CA2877516A patent/CA2877516A1/en not_active Abandoned
- 2013-06-18 MX MX2014015744A patent/MX2014015744A/es unknown
- 2013-06-18 CN CN201380035339.9A patent/CN105579061A/zh active Pending
- 2013-06-18 JP JP2015520289A patent/JP2015526409A/ja not_active Abandoned
- 2013-06-18 KR KR20157001775A patent/KR20150036163A/ko not_active Application Discontinuation
- 2013-06-18 WO PCT/US2013/046399 patent/WO2014007982A2/en active Application Filing
- 2013-06-18 AU AU2013287119A patent/AU2013287119A1/en not_active Abandoned
- 2013-06-18 RU RU2014153675A patent/RU2014153675A/ru not_active Application Discontinuation
- 2013-06-18 EP EP13812620.6A patent/EP2869846A4/en not_active Withdrawn
- 2013-06-18 US US14/410,018 patent/US20150353631A1/en not_active Abandoned
-
2015
- 2015-01-01 IL IL236549A patent/IL236549A0/en unknown
- 2015-09-29 HK HK15109545.4A patent/HK1208810A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014153675A (ru) | 2016-08-27 |
| US20150353631A1 (en) | 2015-12-10 |
| AU2013287119A1 (en) | 2015-01-22 |
| EP2869846A4 (en) | 2016-01-13 |
| KR20150036163A (ko) | 2015-04-07 |
| JP2015526409A (ja) | 2015-09-10 |
| WO2014007982A2 (en) | 2014-01-09 |
| EP2869846A2 (en) | 2015-05-13 |
| CA2877516A1 (en) | 2014-01-03 |
| CN105579061A (zh) | 2016-05-11 |
| HK1208810A1 (en) | 2016-03-18 |
| IL236549A0 (en) | 2015-02-26 |
| WO2014007982A3 (en) | 2014-04-03 |
| MX2014015744A (es) | 2015-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014033066A2 (pt) | método para tratamento de um paciente diagnosticado com doença de alzheimer, forma humanizada, quimérica ou revestida de um anticorpo, e, anticorpo. | |
| IL275092A (en) | Methods for treating Crohn's disease using an anti-IL-23 antibody | |
| HK1194757A1 (zh) | 供人類使用的抗體、可變區與鏈特製 | |
| IL235261B (en) | Antibodies against claudin 18.2 for use in the diagnosis of cancer | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112013018876A2 (pt) | dispositivo de travamento, dispositivo de transferência com o mesmo, e método para controlar o dispositivo de travamento | |
| WO2014152006A3 (en) | Anti-hepcidin antibodies and uses thereof | |
| WO2015010100A3 (en) | Humanized antibodies with ultralong complementarity determining regions | |
| WO2012166626A8 (en) | Reagents and methods for treating dental disease | |
| BR112014031263A2 (pt) | composto, composição farmacêutica, métodos para inibir a secreção wnt e para inibir sinalização wnt, uso do composto ou sal e método para tratar um distúrbio. | |
| BR112013033277A2 (pt) | catalisador de óxido, e, método para produzir o mesmo | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| WO2015017146A3 (en) | Antibodies with ultralong complementarity determining regions | |
| BR112013031117A2 (pt) | scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| EP2723866A4 (en) | METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES | |
| EP3006465A4 (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
| BR112014025299A8 (pt) | anticorpo de reação cruzada dirigido contra staphylococcus aureus, preparação farmacêutica e diagnóstica compreendendo o anticorpo, métodos de anticorpo de reação cruzada contra staphylococcus aureus | |
| FR3004967B1 (fr) | Procede de preparation d'un catalyseur a base de molybdene utilisable en hydrotraitement ou en hydrocraquage | |
| WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
| BR112015003032A2 (pt) | anticorpos anti-jagged e métodos de utilização'. | |
| BR112014010168A2 (pt) | corpo para válvula acionada, válvula acionada correspondente e o processo de fabricação da mesma | |
| EP3086846A4 (en) | Diagnosing and treating alzheimer's disease | |
| SG11201506358PA (en) | Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof | |
| BR112014032290A2 (pt) | composições e métodos para tratar ou prevenir infecção de pneumovírus e doenças associadas. | |
| IL240161A0 (en) | A human antibody specific for human meta-pneumonia virus, or a fragment thereof that binds an antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: WYETH LLC (US) ; JANSSEN SCIENCES IRELAND UC (IE) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |